series-b
Stage
1
Investors
About
Immune-Onc Therapeutics develops clinical-stage biologic therapies that target myeloid cell surface proteins to treat blood cancers, solid tumors, and autoimmune diseases by modulating or depleting specific subsets of myeloid cells involved in disease.
Explore Immune-Onc Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.